Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

LVS Advisory - Growth 2024 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (LVS Advisory - Growth)

Primary Source Intelligence • Q3 2024 Letter Analysis

LVS Advisory - Growth Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, LVS Advisory - Growth. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

YTD+27.1%

Digest Analysis

Quick Take

"Medpace is a niche CRO leader with 20%+ revenue growth and 50%+ ROIC, now trading at attractive low-20s multiples. Temporary biotech funding headwinds create buying opportunity while long-term growth drivers including AI innovation remain intact."

Executive Summary

LVS Growth Portfolio gained 27.1% in the first nine months of 2024, extending its lead versus the S&P 500. The manager increased the position in Medpace, a contract research organization serving small and mid-sized biotech companies through a full-service outsourcing model. Medpace has demonstrated impressive financial metrics with 20%+ organic revenue growth over the past decade, earnings growing faster than revenue, and return on invested capital exceeding 50%. The stock declined over 20% from recent highs due to temporary biotech funding challenges that have reduced R&D spending and clinical trial activity since 2022. The manager views this as a buying opportunity, with Medpace trading at earnings multiples in the low 20s despite superior growth prospects and cash generation. Long-term industry drivers remain intact including innovation in drug discovery, AI adoption, and pharmaceutical companies' need to replenish drug portfolios facing patent expirations. The manager expects the funding environment to improve in a lower interest rate environment.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

Manager demonstrates moderate-high conviction by increasing position size in Medpace after earnings miss, providing detailed fundamental analysis with specific financial metrics (20%+ growth, 50%+ ROIC), and expressing confidence in long-term thesis despite near-term headwinds. Clear position sizing decisions and willingness to add on weakness indicate conviction above average diversified fund level.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager acknowledges near-term uncertainty in the biotech industry and funding challenges but maintains constructive long-term view on innovation drivers and AI adoption. Mixed outlook with cautious optimism.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

Portfolio gained 27.1% YTD and manager is selectively adding to positions including increasing Medpace stake and establishing new cybersecurity position. Demonstrates moderate risk appetite with selective deployment.

Capital Deployment

35%

De-riskingDeploying

Net Neutral (35%)

Manager made selective additions during the quarter including increasing Medpace position, adding to Booz Allen and Talen Energy, and establishing new cybersecurity position. Represents moderate deployment activity with no cash level data provided, suggesting selective capital deployment rather than aggressive or defensive positioning.

Forward Guidance

30%

CautiousExpansionary

Cautious (30%)

Manager expects long-term industry drivers to remain intact and funding environment to potentially improve in lower rate environment, but acknowledges near-term uncertainty. Cautiously optimistic deployment bias.

Language Signal

35%

BearishBullish

Bearish (35%)

Language includes both opportunity-focused terms like 'attractive bargain,' 'buying opportunity,' and 'outstanding results' balanced with risk acknowledgment of 'temporary slowdown,' 'uncertainty,' and 'near-term risks.' Slightly more bullish than bearish overall.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

Manager acknowledges near-term risks from biotech funding challenges and industry uncertainty but characterizes these as temporary. Risk discussion is present but not central to the letter, with emphasis on long-term opportunity outweighing near-term concerns.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

Manager sees selective opportunities with detailed analysis of Medpace as attractive investment and establishment of new cybersecurity position. Characterizes current environment as providing buying opportunities from temporary dislocations, suggesting moderate opportunity density in defined areas.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

Manager emphasizes long-term drivers and expects Medpace to prosper 'over the longer term' while acknowledging near-term risks. Discussion focuses on multi-year thesis with 10-year historical performance analysis and long-term industry trends, indicating patient capital approach typical of growth equity strategies.